Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Cardiovasc Drugs Ther ; 28(4): 323-9, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24984883

RESUMEN

PURPOSE: Aspirin resistance occurs most frequently in diabetic patients and is associated with poor prognosis. The purpose of this study was to evaluate the prevalence of aspirin resistance in a cohort of diabetic patients and whether it can be reversed using more bioavailable aspirin formulations. METHODS: Platelets function of 163 diabetic patients taking acetyl salicylic acid (ASA) 100 mg daily has been evaluated with PFA100 and VerifyNow. Patients found resistant by at least one test received an infusion of 288 mg of lysine acetylsalicylate (Flectadol®) corresponding to ASA 160 mg. Platelets function was measured again after 1 and 24 h. Patients whose the resistance was reversed received 288 mg of soluble salt of lysine acetylsalicylate (Cardirene 160®) corresponding to ASA160 mg instead of aspirin and their aggregation status was re-evaluated after 1 month of therapy. RESULTS: Prevalence of aspirin resistance in our population was 18,4 % (30/163). In 27 out of 30 patients (90 %) aspirin resistance was reversed within 24 h from the infusion. 25 out of 27 patients (92 %) were found fully aspirin-sensitive after 1 month of oral therapy with soluble salt; two patients were found with borderline value. No adverse reactions were observed. CONCLUSIONS: A significant number of diabetic patients are resistant to aspirin therapy. A single intravenous dose of lysine acetylsalicylate can reverse the platelet hyper-aggregability and laboratory aspirin resistance in large majority of patients. The efficacy of antiaggregation can be maintained by chronic therapy with an oral drug with a more favourable pharmacokinetic profile.


Asunto(s)
Aspirina/análogos & derivados , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Resistencia a Medicamentos , Lisina/análogos & derivados , Inhibidores de Agregación Plaquetaria/uso terapéutico , Anciano , Aspirina/uso terapéutico , Química Farmacéutica , Diabetes Mellitus Tipo 2/sangre , Femenino , Humanos , Laboratorios , Lisina/uso terapéutico , Masculino , Persona de Mediana Edad , Proyectos Piloto , Agregación Plaquetaria/efectos de los fármacos
2.
Recenti Prog Med ; 104(3): 112-5, 2013 Mar.
Artículo en Italiano | MEDLINE | ID: mdl-23548955

RESUMEN

The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is a common and multifactorial cause of hyponatremia that is often overlooked. The common pathophysiological mechanism is the increased production and/or action of antidiuretic hormone within the kidney, resulting in hypotonic hyponatremia. Inadequate correction of hyponatremia may have fatal neurological consequences leading to central pontine myelinolysis. We report the case of a patient with a history of recent head trauma, who came to our observation for acute-onset mental confusion secondary to severe hyponatremia due to SIADH of combined etiology.


Asunto(s)
Hiponatremia/etiología , Síndrome de Secreción Inadecuada de ADH/complicaciones , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/uso terapéutico , Antagonistas de los Receptores de Hormonas Antidiuréticas , Benzazepinas/uso terapéutico , Lesiones Encefálicas/complicaciones , Confusión/etiología , Humanos , Hiponatremia/tratamiento farmacológico , Síndrome de Secreción Inadecuada de ADH/fisiopatología , Riñón/fisiopatología , Masculino , Persona de Mediana Edad , Traumatismo Múltiple/complicaciones , Núcleo Hipotalámico Paraventricular/lesiones , Núcleo Hipotalámico Paraventricular/metabolismo , Agitación Psicomotora/etiología , Rabdomiólisis/complicaciones , Solución Salina Hipertónica/uso terapéutico , Núcleo Supraóptico/lesiones , Núcleo Supraóptico/metabolismo , Tolvaptán
3.
J Sex Med ; 8(6): 1694-700, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21477012

RESUMEN

INTRODUCTION: Sexual dysfunction in women with diabetes, despite its important consequences to their quality of life, has been investigated only recently with conflicting results about its prevalence and association with complications and psychological factors. AIMS: To assess the prevalence of the alteration of sexual function and the influence of metabolic control and psychological factors on female sexuality. METHODS: Seventy-seven adult Italian women with type 1 diabetes, matched with a control group (n=77), completed questionnaires evaluating sexual function (Female Sexual Function Index, FSFI), depressive symptoms (Self-Rating Depression Scale, SRDS), social and family support (Multidimensional Scale of Perceived Social Support), and diabetes-related quality of life (Diabetes Quality of Life). Clinical and metabolic data were collected. MAIN OUTCOME MEASURES: Prevalence and magnitude of sexual dysfunction in terms of alteration of sexual functioning as measured by the FSFI scores. RESULTS: The prevalence of sexual dysfunction was similar in diabetes and control groups (33.8% vs. 39.0%, not significant), except for higher SRDS scores in the diabetes group (47.39 ± 11.96 vs. 43.82 ± 10.66; P=0.047). Diabetic patients with an alteration of sexual function showed a significantly higher SRDS score (53.58 ± 14.11 vs. 44.24 ± 9.38, P=0.004). Depression symptoms and good glycemic control (A1C<7.0%) were predictors of alteration of sexual function only in diabetic patients (odds ratio [OR]=1.082; 95% confidence interval [CI]: 1.028-1.140; OR=5.085; 95% CI: 1.087-23.789), since we have not found any significant predictor of sexual dysfunction in the control group. CONCLUSIONS: The prevalence of sexual dysfunction in our type 1 diabetes patients' sample is similar to those reported in other studies. Diabetic patients are similar to healthy people except for higher depression scores. Further studies are necessary to understand whether the correlation between an alteration of sexual function and good glycemic control may be related to the role of control as a mental attitude.


Asunto(s)
Trastorno Depresivo/epidemiología , Trastorno Depresivo/psicología , Diabetes Mellitus Tipo 1/epidemiología , Diabetes Mellitus Tipo 1/psicología , Disfunciones Sexuales Fisiológicas/epidemiología , Disfunciones Sexuales Fisiológicas/psicología , Disfunciones Sexuales Psicológicas/epidemiología , Disfunciones Sexuales Psicológicas/psicología , Ajuste Social , Adulto , Factores de Edad , Estudios de Casos y Controles , Comorbilidad , Estudios Transversales , Trastorno Depresivo/sangre , Diabetes Mellitus Tipo 1/sangre , Femenino , Hemoglobina Glucada/metabolismo , Humanos , Persona de Mediana Edad , Valores de Referencia , Factores de Riesgo , Disfunciones Sexuales Fisiológicas/sangre , Disfunciones Sexuales Psicológicas/sangre
5.
Int J Androl ; 30(6): 531-6, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17376219

RESUMEN

The usefulness of treating varicocele in order to improve fertility is still a matter of debate. The aim of this study was to evaluate variations in seminal parameters and inhibin B concentrations in a group of males affected by varicocele and treated by percutaneous retrograde sclerotherapy in comparison with a group of patients who did not undergo varicocele treatment. Thirty-eight patients with left varicocele underwent spermatic vein phlebography and percutaneous retrograde sclerotherapy with hydroxy-polyaethoxy-dodecanol. Serum inhibin B, follicle-stimulating hormone (FSH), testosterone levels and seminal parameters (sperm concentration, motility and morphology) were performed before and 6 months after sclerotherapy. Forty patients with left varicocele who did not undergo sclerotherapy were studied as controls. A significant increase (p < 0.01) in serum inhibin B levels and a significant decrease (p < 0.05) in FSH levels were observed 6 months after treatment. Semen analysis showed a significant improvement in sperm concentration (p < 0.05) and progressive motility (p < 0.01) after treatment. In control group no significant variations in hormonal and seminal parameters were observed 6 months after the basal examination. Six months after the basal evaluation, inhibin B levels were significantly higher in treated subjects than in controls (p < 0.05) whereas FSH levels were significantly lower (p < 0.05). Sperm concentration and progressive motility were significantly increased (p < 0.05 and p < 0.001, respectively) in treated subjects in comparison with controls. In conclusion, varicocele sclerotherapy improves inhibin B levels and seminal parameters, confirming the positive effect of this treatment on spermatogenesis and Sertoli cell function.


Asunto(s)
Inhibinas/sangre , Polietilenglicoles/uso terapéutico , Soluciones Esclerosantes/uso terapéutico , Escleroterapia , Espermatozoides/patología , Varicocele/terapia , Adolescente , Adulto , Estudios de Casos y Controles , Hormona Folículo Estimulante/sangre , Humanos , Masculino , Flebografía , Polidocanol , Recuento de Espermatozoides , Motilidad Espermática , Espermatogénesis , Testosterona/sangre , Factores de Tiempo , Resultado del Tratamiento , Ultrasonografía Doppler Dúplex , Varicocele/sangre , Varicocele/patología , Varicocele/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA